Skip to content
Open access

HMGN5 promotes renal tubular inflammation and pyroptosis-associated signaling in chronic kidney disease via the IFNAR2 axis

Oct 2026 · International Journal of Molecular Medicine · Vol 58 · 0 citations · 41 references
Medicine

TL;DR

HMGN5 is identified as a novel regulator of IFNAR2-related pyroptosis-associated signaling in renal tubular epithelial cells and it is suggested that the HMGN5-IFNAR2 axis represents a pathophysiological pathway of interest in CKD that warrants further investigation.

Abstract

Chronic kidney disease (CKD) is a condition that is characterized by persistent tubular injury, inflammation and progressive fibrosis, ultimately leading to an irreversible loss of renal function. Pyroptosis, a notably pro-inflammatory mode of programmed cell death, contributes to tubular epithelial injury and amplifies renal inflammwation. The present study investigated the role of high mobility group nucleosome-binding protein 5 (HMGN5) in CKD and its regulatory relationship with interferon (IFN) receptor 2 (IFNAR2) signaling. The present study found that HMGN5 expression was significantly upregulated in renal tissues obtained from patients with CKD and CKD-model mice; this upregulation was accompanied by enhanced renal injury, fibrosis and inflammatory cytokine production. In vitro, HMGN5 overexpression in HK-2 cells: i) Promoted the expression of IFNAR2, phosphorylated-interferon regulatory factor (IRF)3/IRF7 and absent in melanoma 2; ii) enhanced the cleavage of caspase-1 and gasdermin D; iii) increased IL-1β, IL-8 and IFN-β secretion; and iv) promoted lactate dehydrogenase release. These findings suggested the activation of pyroptosis-associated cellular responses. Conversely, silencing HMGN5 or blocking IFNAR2 signaling markedly attenuated these effects. In vivo, pharmacological blockade of IFNAR2 ameliorated renal tissue damage, reduced fibrosis, restored renal function, decreased systemic cytokine levels and suppressed pyroptosis-associated signaling in CKD-model mice. Collectively, the findings of the present study identified HMGN5 as a novel regulator of IFNAR2-related pyroptosis-associated signaling in renal tubular epithelial cells and suggested that the HMGN5-IFNAR2 axis represents a pathophysiological pathway of interest in CKD that warrants further investigation.

Read PDF

Similar papers

Sep 2026

Disruption of cellular iron homeostasis by SRPX2-IRP1 interaction aggravates renal fibrosis in chronic kidney disease.

Findings reveal SRPX2 as a key pathogenic factor driving renal fibrosis by disrupting tubular iron homeostasis and Targeting the SRPX2-IRP1 regulatory axis presents a promising therapeutic strategy for slowing CKD progression.

Pei-Ran Yin, Lu-Miao Chen, M. Ding et al. · 0 citations
Open access Sep 2026

IFN-γ–dominant immune shift is associated with reduced protective ILC2 responses in chronic kidney disease

Findings suggest that IFN-γ–dominant immune polarization is associated with suppression of protective ILC2 responses and exacerbation of CKD, which may provide insights into therapeutic strategies aimed at preserving protective ILC2 responses in CKD.

Yoshihiro Kuno, Hiroki Ishikawa, Ryuichi Nagashima et al. · 0 citations
Open access Oct 2026

Gramine Suppresses Myofibroblast Activation and ECM Accumulation in Renal Fibrosis by Targeting the NF-κB/NLRP3 and TGF-β1/Smad Pathways.

It is demonstrated that GMN attenuates renal inflammation, suppresses myofibroblast activation and ECM remodeling by concurrently inhibiting NF-κB/NLRP3 inflammasome axis and TGF-β1/Smad pathway.

Shobhit Gairola, A. Bhatta, Tushar Mishra et al. · 0 citations
Oct 2026

The Major Iron Transporter DMT1 Promotes Renal Fibrosis by Activating Ferroptosis and Enforcing TGF-β1 Signaling in Renal Tubular Cells.

These findings support a model in which tubular DMT1 integrates iron overload, ferroptotic stress, and TGF-β1-Smad signaling during fibrotic progression in CKD, and may offer a tubular-selective therapeutic strategy for CKD.

Ying Pan, Mei-Qi Liu, Jia-Wei Qiu et al. · 0 citations
Open access Sep 2026

Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses

Chronic kidney disease (CKD) is partly driven by excessive innate immune activation, which contributes to progressive renal injury and fibrosis. Disulfiram (DSF), an approved treatment for alcohol dependence, has recently emerged as an inhibitor of innate immune responses such as pyroptosis. In this study, we investiga...

Saori Kin, Yuji Oe, Shun Ishigaki et al. · 0 citations
Open access Oct 2026

Group IVA Cytosolic Phospholipase A2 (cPLA2α): Pharmacological Inhibition Attenuates Kidney Inflammation and Fibrosis

Chronic kidney disease (CKD) is a significant global health burden and a leading cause of death in the United States. Chronic inflammation contributes to fibrosis and CKD progression. Here, we present evidence that a key pro-inflammatory group IVA phospholipase A2 enzyme (cPLA2α) is critical to the development of kidne...

Berit Johansen, Said Movahedinaini, L. Selvik et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.